Table of Contents
Laboratory Information Management System Market Overview
A Laboratory Information Management System (LIMS) is a software solution that streamlines laboratory processes by managing sample tracking, data storage, and workflow automation.
It centralizes data, ensures regulatory compliance, and improves efficiency by automating tasks and enhancing data accuracy.
Key functions include sample management, quality control, inventory management, and generating reports.
LIMS can be deployed on-premises or in the cloud, with benefits such as better data integrity, scalability, and reduced manual errors.
When selecting a LIMS, factors like laboratory size, integration needs, customization options, and cost should be considered.
Market Drivers
Several factors, including the increasing complexity of laboratory processes, stringent regulatory compliance requirements, and advancements in technology such as cloud computing and automation, drive the global Laboratory Information Management System (LIMS) market.
The demand for accurate data management and integrity, higher laboratory throughput, and the rising trend of outsourcing laboratory services further propel LIMS adoption.
Additionally, the expansion of life sciences and healthcare industries worldwide contributes to the growing need for efficient, compliant, and technologically advanced laboratory management solutions.
Market Size
The global Laboratory Information Management System (LIMS) market is projected to reach USD 4.7 billion by 2033. Growing at a steady CAGR of 10.1% from 2024 to 2033. The market is expected to total USD 2.0 billion in 2023.
List of Major Companies
These are the top 10 companies operating in the Laboratory Information Management System Market:
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories has strengthened its presence in the Laboratory Information Management System (LIMS) sector primarily through the acquisition of STARLIMS Technologies. Which has been a major provider of advanced LIMS solutions.
This acquisition allowed Abbott to integrate cutting-edge web-based systems into its diagnostics division. Streamlining laboratory operations across multiple segments such as clinical, molecular, and point-of-care diagnostics.
Recent developments include the completion of Abbott’s acquisition of Bigfoot Biomedical in 2023. Reflecting its commitment to expanding digital health tools and data management solutions within healthcare.
Geographical Presence
Abbott Laboratories has a broad global presence, with its headquarters in Illinois serving as a central hub for its R&D and manufacturing.
In Europe, the Middle East, and Africa the company operates widely across Western and Eastern Europe, as well as the Middle East and Africa. In Asia-Pacific, Abbott’s key markets include China, India, Japan, South Korea, and Southeast Asia, with a focus on diagnostics and medical devices.
In Latin America, Abbott has major facilities in Brazil and Mexico and is expanding in Argentina, Chile, and Colombia, supporting its diverse global strategy.
Recent Developments
- In August 2024, Abbott Laboratories and Medtronic teamed up to create a new integrated continuous glucose monitoring system.
- In June 2024, Abbott Laboratories and the National Association of Community Health Centers partnered through the Innovation Incubator program to enhance access to nutritious food and health services.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc. has expanded its footprint in the Laboratory Information Management System (LIMS) sector through strategic initiatives like the acquisition of BSSN Software.
This acquisition bolstered Merck’s capabilities in lab data management by integrating software that facilitates communication between lab instruments and systems, making data more accessible and improving digital workflows.
Furthermore, Merck launched the LANEXO™ Lab Inventory, Safety, and Compliance Management System. Which enhances lab efficiency by streamlining inventory management and improving data traceability.
These moves align with Merck’s broader strategy to support digital transformation in laboratories, particularly in the pharmaceutical and research sectors.
Geographical Presence
Merck & Co., Inc., or MSD outside the U.S. and Canada, operates worldwide with a strong presence in major regions.
Headquartered in Kenilworth, New Jersey, Merck’s U.S. and Canadian operations are central to its business.
In Europe, the company is prominent in both Western and Eastern countries such as Germany and Russia. Its Asia-Pacific operations include key markets like Japan, China, and India, as well as Australia and New Zealand.
In Latin America, Brazil and Mexico are major markets, with an additional presence in Argentina and Chile. In the Middle East and Africa, Merck focuses on South Africa and various Middle Eastern countries.
This global reach supports its extensive portfolio of pharmaceuticals, vaccines, and animal health products, supported by a broad network of R&D and manufacturing facilities.
Recent Developments
- In August 2024, Merck agreed to acquire CN201, a novel bispecific antibody in clinical trials for B-cell-related diseases.
- In March 2020, Merck introduced the LANEXO™ Lab Inventory, Safety, and Compliance Management System, a digital solution aimed at significantly reducing lab time while enhancing data quality and traceability.
GSK
Company Overview
| Establishment Year | 2000 |
| Headquarter | London, England, UK |
| Key Management | Emma Walmsley (CEO) |
| Revenue (US$ Bn) | $ 37.7 Billion (2022) |
| Headcount | ~ 70,000 (2024) |
| Website | https://www.gsk.com/ |
About GSK
GSK plc has been advancing its digital transformation in the Laboratory Information Management System (LIMS) sector by focusing on integrating data for research and development (R&D).
The company implemented a comprehensive data platform called the R&D Information Platform (RDIP), which unifies data from various research hubs to streamline decision-making and boost innovation in drug discovery and clinical trials.
In terms of recent acquisitions, GSK made a significant move by acquiring Bellus Health for $2 billion in 2023, which strengthens its portfolio in respiratory diseases.
Additionally, GSK continues to invest in digital solutions aimed at improving data management and lab efficiency, which supports its broader R&D efforts across pharmaceuticals and vaccines.
Geographical Presence
GlaxoSmithKline plc (GSK) operates on a global scale and has a significant geographical presence. In North America, it maintains a strong foothold in the United States and Canada, with extensive R&D and manufacturing facilities.
In Europe, the U.K. serves as its headquarters, while GSK has a notable presence across Western and Eastern Europe. The company is prominent in Asia-Pacific, particularly in China and India, and has established operations throughout the region.
In Latin America, Brazil is a key market, complemented by operations in Argentina, Mexico, and Colombia. In the Middle East and Africa, South Africa is a central hub, with GSK serving various markets across the continent. This extensive network supports GSK’s diverse global operations and strategic objectives.
Recent Development
- In August 2024, GSK received US FDA approval for Jemperli (dostarlimab) combined with chemotherapy to treat adults with advanced or recurrent endometrial cancer.
- In July 2024, GSK planned to acquire CureVac’s experimental vaccines for $430 million.
Thermo-Fisher
Company Overview
| Establishment Year | 1956 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Marc N. Casper (Chairman) |
| Revenue (US$ Bn) | $ 42.8 Billion (2023) |
| Headcount | ~ 122,000 (2023) |
| Website | http://www.thermofisher.com/ |
About Thermo Fisher
Thermo Fisher Scientific Inc. has solidified its role in the Laboratory Information Management System (LIMS) sector by offering advanced data management solutions that streamline laboratory workflows and improve data accuracy.
The company’s Thermo Scientific™ LIMS platforms are widely used in research, development, and manufacturing environments to enhance lab productivity.
Recent developments include Thermo Fisher’s continued investment in acquisitions to expand its capabilities, such as the acquisition of The Binding Site in 2022 for $2.6 billion, which enhances its offerings in diagnostics and clinical trials.
Additionally, Thermo Fisher has focused on expanding its clinical research services, as seen with the opening of a new clinical research laboratory in Wisconsin in 2024, reflecting its commitment to supporting scientific advancements globally.
Geographical Presence
Thermo Fisher Scientific Inc. operates globally and has a significant presence in key regions. In North America, the company is headquartered in Waltham, Massachusetts, with facilities across the U.S. and Canada.
In Europe, Thermo Fisher maintains major sites in the UK, Germany, France, and Switzerland. In the Asia-Pacific region, it has notable operations in China, Japan, and India.
The company is also active in Latin America, with facilities in Brazil and Mexico, as well as in the Middle East and Africa, including South Africa and the UAE. This widespread geographical presence enables Thermo Fisher to support scientific advancements worldwide effectively.
Recent Development
- In August 2024, Thermo Fisher Scientific received FDA approval for its SeCore CDx HLA sequencing system to treat adults with unresectable or metastatic synovial sarcoma.
- In July 2024, Thermo Fisher Scientific acquired Olink Holding AB, a leader in next-generation proteomics.
Revvity
Company Overview
| Establishment Year | 2023 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Prahlad Singh (CEO) |
| Revenue (US$ Bn) | $ 3.0 B (2022) |
| Headcount | ~ 11,000 (2023) |
| Website | http://revvity.com/ |
About Revvity
Revvity, Inc., formerly part of PerkinElmer, is advancing the Laboratory Information Management System (LIMS) sector with innovative solutions.
Their recent launch, the Signals Research Suite, is a cloud-native SaaS platform that integrates workflows across biology, chemistry, and material sciences to enhance research and development.
This platform facilitates seamless data management and analysis, boosting collaboration and decision-making in drug discovery.
Additionally, Revvity introduced the EONIS Q system for neonatal screening, which simplifies the detection of conditions such as spinal muscular atrophy (SMA). These developments highlight Revvity’s focus on improving lab efficiency and driving life sciences innovation.
Geographical Presence
Revvity, Inc. maintains a robust global presence, with key offices in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
In North America, the company is prominent in Silicon Valley, New York City, Austin, Toronto, and Vancouver. European operations include major hubs in London, Berlin, and Paris.
In Asia-Pacific, Revvity is active in Bangalore, Hyderabad, Beijing, Shanghai, and Sydney. Latin American activities are centered in São Paulo, while Dubai and Johannesburg serve as crucial locations in the Middle East and Africa.
This extensive geographical reach supports Revvity’s engagement with diverse technology markets and innovation centers worldwide.
Recent Developments
- In November 2023, Revvity launched a CE-IVD certified EONIS™ Q system that offers molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns for use in CE-marking accepting countries.
- In June 2023, Revvity introduced the Signals Research Suite, a cloud-native SaaS platform that boosts R&D collaboration from drug discovery to specialty chemicals.
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://sanofi.com/ |
About Sanofi
Sanofi has been active in the Laboratory Information Management System (LIMS) sector, leveraging technology to streamline laboratory workflows, especially in its drug development and research processes.
Recently, the company has expanded through key acquisitions, such as the purchase of Provention Bio for $2.9 billion, adding the diabetes drug TZIELD to its portfolio. This move highlights Sanofi’s focus on integrating advanced therapies for managing chronic diseases.
Additionally, Sanofi has been enhancing its rare disease pipeline with the acquisition of Inhibrx in 2024 for $1.7 billion, further solidifying its position in innovative medicine development.
These acquisitions align with the company’s broader strategy of using digital tools and data management systems to accelerate R&D efforts and improve clinical outcomes.
Geographical Presence
Sanofi is a global healthcare company with a substantial presence across multiple regions. Its operations include a major headquarters in Paris, France, and significant facilities in the United States, Canada, Germany, the United Kingdom, and other European countries.
In the Asia-Pacific region, Sanofi has a growing footprint in China, Japan, and India, among other nations. The company is also active in Latin America, with notable operations in Brazil and Mexico, and extends its reach to South Africa and various Middle Eastern and African countries.
This extensive geographical presence supports Sanofi’s comprehensive approach to pharmaceutical innovation, manufacturing, and market engagement worldwide.
Recent Developments
- In July 2024, Sanofi planned to invest $1.4 to $1.6 billion to enhance its long-acting insulin production in Germany.
- In May 2024, Sanofi completed its acquisition of Inhibrx, Inc., integrating SAR447537 (formerly INBRX-101) into its rare disease pipeline. This move highlights Sanofi’s dedication to advancing unique, potentially leading medicines that enhance its existing portfolio.
Roche
Company Overview
| Establishment Year | 1896 |
| Headquarter | Basel, Switzerland |
| Key Management | Thomas Schinecker (CEO) |
| Revenue (US$ Bn) | $ 65.4 Billion (2022) |
| Headcount | ~ 122,000 (2022) |
| Website | http://www.roche.com/ |
About Roche
Roche has been advancing its presence in the Laboratory Information Management System (LIMS) sector, focusing on improving diagnostics and data management capabilities.
One of its key recent acquisitions includes the $295 million purchase of point-of-care (POC) technology from LumiraDx.
Which will enhance Roche’s ability to deliver decentralized healthcare solutions. This acquisition, completed in 2024, is expected to improve access to timely diagnostic results in various healthcare settings.
Additionally, Roche acquired GenMark Diagnostics for $1.8 billion, expanding its molecular diagnostics portfolio with syndromic testing capabilities. Which are essential for detecting multiple pathogens and combating antimicrobial resistance.
Geographical Presence
Roche, headquartered in Basel, Switzerland, has a significant global footprint, with operations across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
In North America, Roche is prominent in the U.S. and Canada, focusing on both pharmaceuticals and diagnostics. Europe serves as a key hub, with major activities in Switzerland, Germany, the U.K., and France.
In the Asia-Pacific region, Roche is expanding rapidly in China and Japan while maintaining a strong presence in Australia. Latin America sees Roche actively engaged in Brazil and Mexico, and in the Middle East and Africa, the company operates notably in South Africa and other countries.
This extensive geographical presence supports Roche’s commitment to delivering innovative healthcare solutions globally.
Recent Developments
- In January 2024, Roche acquired LumiraDx’s point-of-care technologies for $295 million and invested up to $55 million in the platform.
- In May 2021, Roche acquired GenMark Diagnostics for $1.8 billion to enhance its molecular diagnostics portfolio with GenMark’s syndromic testing expertise.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. has been leveraging digital innovation in the Laboratory Information Management System (LIMS) sector to accelerate drug discovery and development.
Through cloud computing, artificial intelligence (AI), and machine learning, Pfizer has optimized clinical trials and manufacturing processes, enabling faster development of medicines like PAXLOVID.
Recently, Pfizer completed the $43 billion acquisition of Seagen, significantly expanding its oncology portfolio with advanced cancer therapies.
This acquisition strengthens Pfizer’s capabilities in next-generation antibody-drug conjugate (ADC) technology, further driving its research in cancer treatment.
Geographical Presence
Pfizer operates on a global scale and has a significant presence across various regions. Its headquarters are in New York City, and the company maintains extensive research, development, and manufacturing facilities in the United States and Canada.
In Europe, Pfizer has operations in major Western and Eastern European countries, with its European headquarters in Berlin.
The company is also well-established in Asia-Pacific, with significant activities in China, Japan, Australia, and New Zealand. In Latin America, Pfizer has notable operations in Brazil, Argentina, and Mexico.
Additionally, the company is expanding its footprint in the Middle East and Africa, with operations in countries such as Saudi Arabia, South Africa, and Kenya. This extensive geographical presence supports Pfizer’s global drug development, manufacturing, and distribution efforts.
Recent Development
- In June 2024, Pfizer received approval in Japan to develop and market Zabicefta Combination Intravenous Infusion, a beta-lactamase inhibitor combination antibiotic.
- In December 2023, Pfizer completed the acquisition of Seagen Inc., a biotech firm specializing in innovative cancer treatments.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (CEO) |
| Revenue (US$ Bn) | $ 1.9 Billion (2023) |
| Headcount | ~ 5,967 (2023) |
| Website | http://qiagen.com/ |
About Qiagen
Qiagen is actively involved in the Laboratory Information Management System sector, particularly through its diagnostic solutions.
The company offers the QIAstat-Dx platform, which enables rapid multiplex syndromic testing. Including the detection of over 21 respiratory pathogens, such as influenza viruses. This system delivers results in about an hour, aiding in timely and accurate flu diagnosis.
In 2023, Qiagen completed the acquisition of Verogen, further enhancing its capabilities in genetic testing and forensic applications.
Additionally, Qiagen continues to innovate with new product launches, such as digital PCR and next-generation sequencing tools. Although these are more focused on oncology and other research areas.
Geographical Presence
Qiagen NV, a global leader in molecular diagnostics and biotechnology, has a substantial international presence with operations across multiple continents. Its headquarters is in Hilden, Germany, and serves as a central hub complemented by significant facilities in the U.S. and Canada.
In Europe, Qiagen maintains offices in key countries, including the UK, France, Italy, and Spain. The company has a strong footprint in Asia-Pacific, with notable operations in China, Japan, and Australia. It is also established in Latin America through its presence in Brazil and Mexico.
In the Middle East and Africa, Qiagen operates in South Africa and the UAE. This extensive geographical reach supports Qiagen’s strategy to address diverse market needs and drive growth across global regions.
Recent Developments
- In June 2024, Qiagen launched the clinical decision support software QIAGEN Clinical Insight Interpret.
- In January 2023, Qiagen acquired Verogen, a next-generation sequencing firm, to enhance its capabilities in human identification and forensics.
Illumina
Company Overview
| Establishment Year | 1998 |
| Headquarter | San Diego, California, U.S. |
| Key Management | Jacob Thaysen (CEO) |
| Revenue (US$ Bn) | $ 4.5 Billion (2023) |
| Headcount | ~ 9,250 (2023) |
| Website | https://www.illumina.com/ |
About Illumina
Illumina, Inc. plays a key role in the Laboratory Information Management System (LIMS) sector by offering solutions that streamline genetic analysis workflows.
Through the acquisition of GenoLogics Life Sciences Software in 2015, Illumina enhanced its portfolio with Clarity LIMS, a widely adopted platform used in over 120 genomic labs worldwide.
This platform enables laboratories to manage complex sequencing data with greater accuracy, efficiency, and traceability.
Recently, Illumina has continued to innovate with product launches such as the NextSeq 1000/2000 kits, offering longer read lengths for advanced genomic applications like immune-repertoire profiling.
The company also integrates informatics solutions like the DRAGEN Bio-IT platform to optimize whole-genome sequencing for global health challenges, such as genetic disease diagnosis and cancer research.
Geographical Presence
Illumina, Inc. has a significant global presence, with its headquarters in San Diego, California. In North America, it operates major R&D and support facilities in the United States and has distribution channels in Canada.
In Europe, Illumina maintains key operations in the United Kingdom, Germany, and France, among other countries.
Further, In the Asia-Pacific region, it has notable offices and facilities in China, Japan, and Australia, with additional activity in South Korea, India, and Southeast Asia. In Latin America, the company serves markets through operations in Brazil and Mexico.
At the same time, in the Middle East and Africa, it has a growing presence in South Africa and other countries through strategic partnerships and distributors. This extensive network underscores Illumina’s commitment to advancing genomics research and clinical applications worldwide.
Recent Developments
- In July 2024, Illumina acquired Fluent BioSciences, known for its innovative single-cell technology.
- In May 2024, Illumina and Garvan Institute jointly invested in single-cell disease research.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
